StockData
West Pharmaceutical Services Inc logo

West Pharmaceutical Services Inc (WST) stock

WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3031% above fair value
$404.02−10.10 (-2.44%)

Close on Nov 18, 2026Market cap $28.14BP/E 45.3Yield 0.21%

West Pharmaceutical Services operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

West Pharmaceutical Services's operating income for the twelve months ending Sep 30, 2026 was $780.20M, up 32.7% year over year. For fiscal 2025 it was $584.90M, up 2.6% from the year before. Over ten years it grew 16.4% a year on average. The highest annual figure on record is $752.30M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$584.90M+2.6%
FY2024Dec 31, 2024$569.90M-15.7%
FY2023Dec 31, 2023$676.00M-7.9%
FY2022Dec 31, 2022$734.00M-2.4%
FY2021Dec 31, 2021$752.30M+84.9%
FY2020Dec 31, 2020$406.90M+37.2%
FY2019Dec 31, 2019$296.60M+23.4%
FY2018Dec 31, 2018$240.30M+6.4%
FY2017Dec 31, 2017$225.80M+15.7%
FY2016Dec 31, 2016$195.20M+51.8%
FY2015Dec 31, 2015$128.60M-29.3%
FY2014Dec 31, 2014$182.00M+12.1%
FY2013Dec 31, 2013$162.40M+20.2%
FY2012Dec 31, 2012$135.10M+23.3%
FY2011Dec 31, 2011$109.60M+20.8%
FY2010Dec 31, 2010$90.70M-7.0%
FY2009Dec 31, 2009$97.50M-21.4%
FY2008Dec 31, 2008$124.10M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$267.40M+59.5%
Q2 FY2026Jun 30, 2026$179.10M+16.5%
Q1 FY2026Mar 31, 2026$177.10M+65.5%
Q4 FY2025Dec 31, 2025$156.60M-1.9%
Q3 FY2025Sep 30, 2025$167.60M+3.9%
Q2 FY2025Jun 30, 2025$153.70M+21.8%
Q1 FY2025Mar 31, 2025$107.00M-12.9%
Q4 FY2024Dec 31, 2024$159.60M-0.8%
Q3 FY2024Sep 30, 2024$161.30M-9.0%
Q2 FY2024Jun 30, 2024$126.20M-30.8%
Q1 FY2024Mar 31, 2024$122.80M-20.9%
Q4 FY2023Dec 31, 2023$160.90M+24.1%
Q3 FY2023Sep 30, 2023$177.30M-4.8%
Q2 FY2023Jun 30, 2023$182.50M-20.1%
Q1 FY2023Mar 31, 2023$155.30M-18.1%
Q4 FY2022Dec 31, 2022$129.70M-29.5%
Q3 FY2022Sep 30, 2022$186.20M+2.6%
Q2 FY2022Jun 30, 2022$228.40M+8.1%
Q1 FY2022Mar 31, 2022$189.70M+8.0%
Q4 FY2021Dec 31, 2021$184.00M+58.5%
Q3 FY2021Sep 30, 2021$181.40M+82.9%
Q2 FY2021Jun 30, 2021$211.30M+104.0%
Q1 FY2021Mar 31, 2021$175.60M+99.5%
Q4 FY2020Dec 31, 2020$116.10M+48.7%
Q3 FY2020Sep 30, 2020$99.20M+47.4%
Q2 FY2020Jun 30, 2020$103.60M+28.7%
Q1 FY2020Mar 31, 2020$88.00M+24.5%
Q4 FY2019Dec 31, 2019$78.10M+18.7%
Q3 FY2019Sep 30, 2019$67.30M+10.7%
Q2 FY2019Jun 30, 2019$80.50M+33.5%
Q1 FY2019Mar 31, 2019$70.70M+32.4%
Q4 FY2018Dec 31, 2018$65.80M+8.9%
Q3 FY2018Sep 30, 2018$60.80M-3.3%
Q2 FY2018Jun 30, 2018$60.30M+43.6%
Q1 FY2018Mar 31, 2018$53.40M-11.7%
Q4 FY2017Dec 31, 2017$60.40M+14.6%
Q3 FY2017Sep 30, 2017$62.90M–
Q2 FY2017Jun 30, 2017$42.00M–
Q1 FY2017Mar 31, 2017$60.50M–
Q4 FY2016Dec 31, 2016$52.70M–

More West Pharmaceutical Services figures

See a number that looks wrong?